Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Receivables - Other (2016 - 2025)

China Pharma Holdings filings provide 15 years of Receivables - Other readings, the most recent being $49261.0 for Q4 2025.

  • On a quarterly basis, Receivables - Other rose 62.65% to $49261.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $49261.0, a 62.65% increase, with the full-year FY2025 number at $49261.0, up 62.65% from a year prior.
  • Receivables - Other hit $49261.0 in Q4 2025 for China Pharma Holdings, down from $61275.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $1.7 million in Q3 2021 to a low of $28660.0 in Q2 2024.
  • Median Receivables - Other over the past 5 years was $55268.0 (2025), compared with a mean of $523462.9.
  • Biggest five-year swings in Receivables - Other: plummeted 97.96% in 2022 and later surged 442.04% in 2023.
  • China Pharma Holdings' Receivables - Other stood at $1.4 million in 2021, then plummeted by 97.96% to $29139.0 in 2022, then surged by 442.04% to $157944.0 in 2023, then plummeted by 80.82% to $30286.0 in 2024, then skyrocketed by 62.65% to $49261.0 in 2025.
  • The last three reported values for Receivables - Other were $49261.0 (Q4 2025), $61275.0 (Q3 2025), and $48361.0 (Q2 2025) per Business Quant data.